THE PROGRAMME
№
|
Topic
|
Hours
|
1.
|
The causative agent of tuberculosis (TB), structure, metabolism,
pathogenesis and molecular determinants of virulence. Classification
of Mycobacterium species. Epidemiological indicators of TB burden. Global
and national TB epidemiology. TB transmission. Pathogenesis
of tuberculosis. Immunity to TB. Clinical classification of tuberculosis.
Latent TB infection. Risk groups. Primary and Post Primary TB (basic images
and sequelae).
|
4
|
2.
|
Clinical presentation of TB. Cough management in primary care settings.
Laboratory diagnostics of tuberculosis. Sputum AFB microscopy. Rules of
specimen’s collection. Bacteriological and molecular methods of detection of M. tuberculosis. Benefits and
drawbacks of phenotypic and genotypic lab methods. Chest radiography, CT scanning
and MRI in TB detection. Descriptive terminology and types of imaging. Typical and atypical presentations of Pulmonary TB on a Chest X-Ray.
Tuberculin Skin Test (TST). Interferon-Gamma Release Assays (IGRA).
Interpretation of TST and IGRA results. Other
tools to confirm TB diagnosis. Clinical case analysis.
|
4
|
3.
|
Pulmonary, extrapulmonary, and combined localisation of tuberculosis.
Generalised (milliary) TB. TB meningitis. TB of peripheral lymph nodes.
Tuberculous pleurisy.
TB in children. BCG vaccination. Differences of TB disease in
vaccinated and non-vaccinated children. Clinical case analysis.
|
4
|
4.
|
Clinical management of tuberculosis. Anti-TB medicines. Standardised
and individualised regimens of treatment. Drug-resistant strains of M. tuberculosis: mono-, poly-, MDR and
XDR-TB. Active monitoring and management of adverse events of anti-TB drugs. Recording standardized treatment outcomes. Directly
Observed Therapy. Ambulatory and inpatient treatment of tuberculosis.
Adherence to treatment. Surgical treatment of TB. Palliative care. Fighting
TB stigma and discrimination. Clinical case analysis.
|
4
|
5.
|
Prevention of tuberculosis. Infection Control: administrative,
engineering and respiratory protection levels. Contact Tracing. BCG
Vaccination. Preventive chemotherapy. TB health care policy. Clinical case
analysis.
|
4
|
6.
|
Trends in Tuberculosis/Human Immunodeficiency Virus Comorbidity.
Management of TB/HIV co-infection. Antiretroviral Therapy for Patients with
HIV and Active Tuberculosis. Tuberculosis-Associated
Immune Reconstitution Inflammatory Syndrome. Clinical case analysis.
|
4
|
Assessing co-morbidities and other factors which could affect outcomes
of TB treatment: diabetes mellitus, pneumoconiosis, immunosuppressive
medicines, anti-TNFα therapy, kidney disease, pregnancy. Life-threatening complications of TB
requiring Intensive Care Unit (ICU) admission: pneumothorax, lung hemorrhage,
airway obstruction, anaphylaxis.
|
4
|
|
Module
|
||
Total
|
28
|
